comparemela.com

Latest Breaking News On - Naomi eichenbaum - Page 13 : comparemela.com

Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

SAN DIEGO, April 01, 2023 Travere Therapeutics, Inc. today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT. | April 1, 2023

Krung thep mahanakhonUnited statesNaomi eichenbaumNivi nehraBrad rovinDivision for nephrologyCompany annual report on formExchange commissionEuropean unionGlobenewswire incOhio state university centerWorld congressTravere therapeutics incClinical research managementCorporate communicationsMedical director

Travere Therapeutics, Inc : Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal

United statesKrung thep mahanakhonNivi nehraNaomi eichenbaumBrad rovinEuropean unionOhio state university centerDivision for nephrologyExchange commissionCorporate communicationsWorld congressClinical research managementCompany annual report on formTravere therapeutics incMedical directorAbout iga

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

Naomi eichenbaumNivi nehraTravere therapeutics incHealth care conferenceCorporate communicationsHealthcare talksGenomic medicinesRare diseaseTravere therapeutics

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Day.

Naomi eichenbaumNivi nehraCorporate communicationsHealth care conferenceTravere therapeutics incHealthcare talksGenomic medicinesRare diseaseTravere therapeutics

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

SAN DIEGO, March 23, 2023 Travere Therapeutics, Inc. today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating. | March 23, 2023

Krung thep mahanakhonUnited statesNivi nehraNaomi eichenbaumCompany annual report on formEuropean unionExchange commissionCorporate communicationsBits associationWorld congressTravere therapeutics incClinical meetingsDual endothelin angiotensin receptor antagonistReduces proteinuriaInterim resultsLate breaking clinical

vimarsana © 2020. All Rights Reserved.